Stocks turned positive Thursday after opening lower, as market participants nervously eyed rising coronavirus cases in major regions throughout the country. Meanwhile, a report showed new weekly unemployment insurance claims were worse than expected last week, with the level down just slightly from the prior week....
Arun Sundaram, CFRA analyst joins Yahoo Finance’s Alexis Christoforous and Brian Sozzi to break down Kroger’s first-quarter earnings report, how the grocery giant can compete with its competitors and more. ...
As the number of new COVID-19 infections spikes, so has market volatility. An uptick in cases in the U.S. and China has spurred the latest burst of swings, with both the S&P 500 and Dow Jones following up their three-session winning streaks by heading back to the red on Wednesday. That being said, one group of stocks has been steadily gaining traction. Small-caps, or names with market caps below $2 billion, have led the pack, with the Russell 2000’s rebound from its March 23 low point exceeding the S&P 500’s gain over the same time period.Taking all of this into consideration, we set out to find compelling small-cap stocks that combine a low cost of entry with the Street’s backing. Using TipRanks’ database, we pinpointed two that fit the bill. Not only are the tickers currently going for less than $8 apiece, but each has also received enough bullish support from...
In the last 24 hours, Spotify scored two major podcast deals. Yahoo Finance’s Ines Ferre breaks down the details of Spotify’s latest podcast deals. ...
It seems that just about everyone -- Germany, France, Italy, the Netherlands, the U.S. -- have put their money on AstraZeneca's (NYSE: AZN) novel coronavirus vaccine. But the European Commission is preparing to bet on another contender.What To Know: The Commission called Johnson & Johnson (NYSE: JNJ) Tuesday about the possibility of reserving or purchasing up-front doses of the company's yet-untested Covid-19 vaccine, according to Reuters. The sales agreement is in late-stage discussions.The EU's 27 composite governments had mandated the commission to use a $2.3 billion emergency fund to make such arrangements with up to six vaccine-producing pharmaceuticals.Why It's Important: "Johnson and Johnson's vaccine is one of the promising initiatives," a Dutch health ministry spokesman familiar with the EU negotiations told Reuters. The Commission is also in talks with Sanofi SA (NASDAQ: SNY).The Johnson & Johnson deal could be announced by next week but may not be finalized for some time...
